| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
5'''-O-Feruloyl complanatoside B's molecular targets are not well-characterized. As a flavonoid from Astragalus complanatus seeds, it may share biological activities with other flavonoids, including antioxidant, anti-inflammatory, and cardiovascular protective effects. Astragalus extracts have been reported to be associated with chronic diseases such as cardiovascular disease, diabetes, and cancer, suggesting potential activity on pathways involved in these conditions. However, specific molecular targets have not been identified.
|
|---|---|
| ln Vitro |
In vitro activity data for 5'''-O-Feruloyl complanatoside B are limited in the published literature. The compound has been primarily characterized as a natural product from Astragalus complanatus seeds. As a flavonoid, it may exhibit antioxidant, anti-inflammatory, or other biological activities. Astragalus seeds have been reported to be associated with chronic diseases such as cardiovascular disease, diabetes, and cancer. However, detailed in vitro activity data are not extensively published.
|
| ln Vivo |
In vivo activity data for 5'''-O-Feruloyl complanatoside B are not available in the published literature. The compound has been primarily characterized as a natural product from Astragalus complanatus seeds. No in vivo pharmacological studies have been reported for this compound. Further research is needed to evaluate its potential biological activities in animal models. The compound's natural occurrence in seeds used in traditional medicine suggests potential for biological activity.
|
| Enzyme Assay |
In vitro assays for 5'''-O-Feruloyl complanatoside B are not extensively documented. As a flavonoid, potential assays could include antioxidant activity evaluation using DPPH or ABTS radical scavenging assays. The compound's structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC with purity ≥98%. Standard flavonoid characterization methods may be applied.
|
| Cell Assay |
In vitro cellular assays for 5'''-O-Feruloyl complanatoside B are not extensively documented. As a flavonoid from Astragalus complanatus, potential cellular assays could include evaluation of antioxidant activity in cell-based oxidative stress models, anti-inflammatory activity in immune cells, or effects on cardiovascular-related cell types. The compound is typically handled as a powder and stored desiccated at -20°C.
|
| Animal Protocol |
In vivo animal experiments for 5'''-O-Feruloyl complanatoside B have not been reported in the published literature. The compound has been studied primarily as a natural product from Astragalus complanatus seeds. No animal studies have been conducted to evaluate its pharmacological effects, toxicity, or pharmacokinetics. Further research would be required to investigate its potential therapeutic applications in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 5'''-O-Feruloyl complanatoside B have not been characterized. The compound has a molecular weight of 932.83 g/mol and molecular formula C₄₃H₄₈O₂₃. As a large glycosylated flavonoid with a feruloyl ester group, it is expected to have very limited oral bioavailability due to its large size and hydrophilic nature. The compound may undergo hydrolysis in the gastrointestinal tract. Storage: desiccate at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 5'''-O-Feruloyl complanatoside B is not extensively documented. As a flavonoid from Astragalus complanatus seeds, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
5'''-O-Feruloyl complanatoside B (CAS# 142473-98-1, molecular formula C₄₃H₄₈O₂₃, molecular weight 932.83) is a flavonoid from Astragalus complanatus seeds. Associated with cardiovascular disease, diabetes, and cancer research. No clinical trials or regulatory approvals have been identified. Purity: ≥98%.
|
| Molecular Formula |
C43H48O23
|
|---|---|
| Exact Mass |
932.258
|
| CAS # |
142473-98-1
|
| PubChem CID |
145874197
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
23
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
66
|
| Complexity |
1690
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
COC1=CC(=C2C(=C1)OC(=C(C2=O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O[C@H]4[C@@H]([C@](CO4)(COC(=O)/C=C/C5=CC(=C(C=C5)O)OC)O)O)C6=CC=C(C=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O
|
| InChi Key |
UTPCLOFGDXGRFY-KVDBRUDJSA-N
|
| InChi Code |
InChI=1S/C43H48O23/c1-57-21-12-23(47)29-25(13-21)62-36(19-5-7-20(8-6-19)61-40-35(54)33(52)30(49)26(14-44)63-40)37(32(29)51)65-41-38(34(53)31(50)27(15-45)64-41)66-42-39(55)43(56,17-60-42)16-59-28(48)10-4-18-3-9-22(46)24(11-18)58-2/h3-13,26-27,30-31,33-35,38-42,44-47,49-50,52-56H,14-17H2,1-2H3/b10-4+/t26-,27-,30-,31-,33+,34+,35-,38-,39+,40-,41+,42+,43-/m1/s1
|
| Chemical Name |
[(3S,4R,5S)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-2-[5-hydroxy-7-methoxy-4-oxo-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-3-yl]oxy-6-(hydroxymethyl)oxan-3-yl]oxy-3,4-dihydroxyoxolan-3-yl]methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
